Belatacept用于同时避免钙调神经磷酸酶抑制剂和慢性糖皮质激素免疫抑制:前瞻性随机多中心试验的两年结果
该随机多中心试验纳入316例新肾移植受者,比较Belatacept联合阿仑单抗或rATG诱导与他克莫司联合rATG诱导的两年结局。复合终点(死亡、移植物丢失或eGFR<45)发生率三组相似,Belatacept组eGFR<45显著降低但活检证实的急性排斥显著增高。
要点
- Belatacept方案eGFR<45发生率显著低于他克莫司方案。
- Belatacept方案活检证实的急性排斥发生率显著高于他克莫司方案。
- 两组患者和移植物生存率相似,胃肠道和神经系统不良事件Belatacept组较少。
核心结论
- Belatacept与他克莫司维持免疫抑制的两年总体结局相似,均采用快速激素撤除。
- Belatacept组eGFR<45的发生率显著低于他克莫司组,但活检证实的急性排斥发生率显著更高。
研究设计与样本
- 随机、前瞻性、多中心研究,纳入316例新肾移植受者,按1:1:1随机分配。
- 三组分别为Belatacept联合阿仑单抗诱导、Belatacept联合rATG诱导、他克莫司联合rATG诱导。
- 所有肾移植均采用快速激素撤除免疫抑制。
主要发现
- 复合终点(死亡、移植物丢失或eGFR<45)发生率:Belatacept/阿仑单抗组11/107(10%),Belatacept/rATG组13/104(13%),他克莫司/rATG组21/105(21%)。
- eGFR<45发生率:Belatacept/阿仑单抗组9/107(8%),Belatacept/rATG组8/104(8%),他克莫司/rATG组20/105(19%)。
- 活检证实的急性排斥发生率:Belatacept/阿仑单抗组20/107(19%),Belatacept/rATG组26/104(25%),他克莫司/rATG组7/105(7%)。
- 患者和移植物生存率三组相似。
- 胃肠道和神经系统不良事件Belatacept组少于钙调神经磷酸酶抑制剂组。
关键数值与推荐
- 复合终点比较:Belatacept/阿仑单抗 vs 他克莫司/rATG,P=0.99;Belatacept/rATG vs 他克莫司/rATG,P=0.66。
- eGFR<45比较:每个Belatacept组 vs 他克莫司/rATG,P<0.05。
- 急性排斥比较:Belatacept/阿仑单抗 vs 他克莫司/rATG,P=0.006;Belatacept/rATG vs 他克莫司/rATG,P<0.001。
临床怎么用
- Belatacept方案可显著降低eGFR<45的风险,但需警惕急性排斥风险增高。
- 对于急性排斥风险较高的受者,选择Belatacept方案时应谨慎评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Immunosuppressive therapy in kidney transplantation is associated with numerous toxicities. CD28-mediated T-cell costimulation blockade using belatacept may reduce long-term nephrotoxicity, compared with calcineurin inhibitor-based immunosuppression. The efficacy and safety of simultaneous calcineurin inhibitor avoidance and rapid steroid withdrawal were tested in a randomized, prospective, multicenter study. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This study reports the 2-year results of a randomized clinical trial of 316 recipients of a new kidney transplant. All kidney transplants were performed using rapid steroid withdrawal immunosuppression. Recipients were randomized in a 1:1:1 ratio to receive belatacept with alemtuzumab induction, belatacept with rabbit anti-thymocyte globulin (rATG) induction, or tacrolimus with rATG induction. The composite end point consisted of death, kidney allograft loss, or an eGFR of <45 ml/min per 1.73 m2 at 2 years. RESULTS: The composite end point was observed for 11 of 107 (10%) participants assigned to belatacept/alemtuzumab, 13 of 104 (13%) participants assigned to belatacept/rATG, and 21 of 105 (21%) participants assigned to tacrolimus/rATG (for belatacept/alemtuzumab versus tacrolimus/rATG, P=0.99; for belatacept/rATG versus tacrolimus/rATG, P=0.66). Patient and graft survival rates were similar between all groups. An eGFR of <45 ml/min per 1.73 m2 was observed for nine of 107 (8%) participants assigned to belatacept/alemtuzuab, eight of 104 (8%) participants assigned to belatacept/rATG, and 20 of 105 (19%) participants assigned to tacrolimus/rATG (P<0.05 for each belatacept group versus tacrolimus/rATG). Biopsy sample-proven acute rejection was observed for 20 of 107 (19%) participants assigned to belatacept/alemtuzuab, 26 of 104 (25%) participants assigned to belatacept/rATG, and seven of 105 (7%) participants assigned to tacrolimus/rATG (for belatacept/alemtuzumab versus tacrolimus/rATG, P=0.006; for belatacept/rATG versus tacrolimus/rATG, P<0.001). Gastrointestinal and neurologic adverse events were less frequent with belatacept versus calcineurin-based immunosuppression. CONCLUSIONS: Overall 2-year outcomes were similar when comparing maintenance immunosuppression using belatacept versus tacrolimus, and each protocol involved rapid steroid withdrawal. The incidence of an eGFR of <45 ml/min per 1.73 m2 was significantly lower with belatacept compared with tacrolimus, but the incidence of biopsy sample-proven acute rejection significantly higher. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: Belatacept Early Steroid Withdrawal Trial, NCT01729494.
引用
- Kaufman DB, Woodle ES, Shields AR, et al. Belatacept for Simultaneous Calcineurin Inhibitor and Chronic Corticosteroid Immunosuppression Avoidance: Two-Year Results of a Prospective, Randomized Multicenter Trial. Clin J Am Soc Nephrol. 2021. PMID: 34233921. doi:10.2215/CJN.13100820
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。